Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Identifieur interne : 000708 ( Main/Curation ); précédent : 000707; suivant : 000709Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Auteurs : Vincenzo Montesarchio [Italie] ; Roberto Parrela [Italie] ; Chiara Iommelli [Italie] ; Antonella Bianco [Italie] ; Elio Manzillo [Italie] ; Fiorentino Fraganza [Italie] ; Cristiana Palumbo [Italie] ; Gaetano Rea [Italie] ; Patrizia Murino [Italie] ; Rosanna De Rosa [Italie] ; Luigi Atripaldi [Italie] ; Maurizio D'Abbraccio [Italie] ; Marcello Curvietto [Italie] ; Domenico Mallardo [Italie] ; Egidio Celentano [Italie] ; Antonio Maria Grimaldi [Italie] ; Marco Palla [Italie] ; Claudia Trojaniello [Italie] ; Maria Grazia Vitale [Italie] ; Samuel Lewis Million-Weaver [États-Unis] ; Paolo Antonio Ascierto [Oman]Source :
- Journal for immunotherapy of cancer [ 2051-1426 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Biomarqueurs pharmacologiques (sang), Femelle (MeSH), Granulocytes neutrophiles (MeSH), Humains (MeSH), Infections à coronavirus (complications), Infections à coronavirus (imagerie diagnostique), Infections à coronavirus (traitement médicamenteux), Interleukine-6 (sang), Italie (MeSH), Mâle (MeSH), Numération des lymphocytes (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (imagerie diagnostique), Pneumopathie virale (traitement médicamenteux), Récepteurs à l'interleukine-6 (antagonistes et inhibiteurs), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Études rétrospectives (MeSH).
- MESH :
- antagonistes et inhibiteurs : Récepteurs à l'interleukine-6.
- imagerie diagnostique : Infections à coronavirus, Pneumopathie virale.
- sang : Biomarqueurs pharmacologiques, Infections à coronavirus, Interleukine-6, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antiviraux.
- Adulte d'âge moyen, Femelle, Granulocytes neutrophiles, Humains, Italie, Mâle, Numération des lymphocytes, Pandémies, Résultat thérapeutique, Sujet âgé, Études rétrospectives.
- Wicri :
- geographic : Italie.
English descriptors
- KwdEn :
- Aged (MeSH), Antibodies, Monoclonal, Humanized (therapeutic use), Antiviral Agents (therapeutic use), Biomarkers, Pharmacological (blood), Coronavirus Infections (complications), Coronavirus Infections (diagnostic imaging), Coronavirus Infections (drug therapy), Female (MeSH), Humans (MeSH), Interleukin-6 (blood), Italy (MeSH), Lymphocyte Count (MeSH), Male (MeSH), Middle Aged (MeSH), Neutrophils (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (diagnostic imaging), Pneumonia, Viral (drug therapy), Receptors, Interleukin-6 (antagonists & inhibitors), Retrospective Studies (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Receptors, Interleukin-6.
- chemical , blood : Biomarkers, Pharmacological, Interleukin-6.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antiviral Agents.
- geographic : Italy.
- complications : Coronavirus Infections, Pneumonia, Viral.
- diagnostic imaging : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Aged, Female, Humans, Lymphocyte Count, Male, Middle Aged, Neutrophils, Pandemics, Retrospective Studies, Treatment Outcome.
Abstract
BACKGROUND
The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing.
STUDY DESCRIPTION
In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease.
CONCLUSIONS
This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.
DOI: 10.1136/jitc-2020-001089
PubMed: 32784217
PubMed Central: PMC7418768
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000708
Links to Exploration step
pubmed:32784217Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.</title>
<author><name sortKey="Montesarchio, Vincenzo" sort="Montesarchio, Vincenzo" uniqKey="Montesarchio V" first="Vincenzo" last="Montesarchio">Vincenzo Montesarchio</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Parrela, Roberto" sort="Parrela, Roberto" uniqKey="Parrela R" first="Roberto" last="Parrela">Roberto Parrela</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Iommelli, Chiara" sort="Iommelli, Chiara" uniqKey="Iommelli C" first="Chiara" last="Iommelli">Chiara Iommelli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bianco, Antonella" sort="Bianco, Antonella" uniqKey="Bianco A" first="Antonella" last="Bianco">Antonella Bianco</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Manzillo, Elio" sort="Manzillo, Elio" uniqKey="Manzillo E" first="Elio" last="Manzillo">Elio Manzillo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fraganza, Fiorentino" sort="Fraganza, Fiorentino" uniqKey="Fraganza F" first="Fiorentino" last="Fraganza">Fiorentino Fraganza</name>
<affiliation wicri:level="1"><nlm:affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Palumbo, Cristiana" sort="Palumbo, Cristiana" uniqKey="Palumbo C" first="Cristiana" last="Palumbo">Cristiana Palumbo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rea, Gaetano" sort="Rea, Gaetano" uniqKey="Rea G" first="Gaetano" last="Rea">Gaetano Rea</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Murino, Patrizia" sort="Murino, Patrizia" uniqKey="Murino P" first="Patrizia" last="Murino">Patrizia Murino</name>
<affiliation wicri:level="1"><nlm:affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Rosa, Rosanna" sort="De Rosa, Rosanna" uniqKey="De Rosa R" first="Rosanna" last="De Rosa">Rosanna De Rosa</name>
<affiliation wicri:level="1"><nlm:affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Atripaldi, Luigi" sort="Atripaldi, Luigi" uniqKey="Atripaldi L" first="Luigi" last="Atripaldi">Luigi Atripaldi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="D Abbraccio, Maurizio" sort="D Abbraccio, Maurizio" uniqKey="D Abbraccio M" first="Maurizio" last="D'Abbraccio">Maurizio D'Abbraccio</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Curvietto, Marcello" sort="Curvietto, Marcello" uniqKey="Curvietto M" first="Marcello" last="Curvietto">Marcello Curvietto</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mallardo, Domenico" sort="Mallardo, Domenico" uniqKey="Mallardo D" first="Domenico" last="Mallardo">Domenico Mallardo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Celentano, Egidio" sort="Celentano, Egidio" uniqKey="Celentano E" first="Egidio" last="Celentano">Egidio Celentano</name>
<affiliation wicri:level="1"><nlm:affiliation>Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Grimaldi, Antonio Maria" sort="Grimaldi, Antonio Maria" uniqKey="Grimaldi A" first="Antonio Maria" last="Grimaldi">Antonio Maria Grimaldi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Palla, Marco" sort="Palla, Marco" uniqKey="Palla M" first="Marco" last="Palla">Marco Palla</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trojaniello, Claudia" sort="Trojaniello, Claudia" uniqKey="Trojaniello C" first="Claudia" last="Trojaniello">Claudia Trojaniello</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vitale, Maria Grazia" sort="Vitale, Maria Grazia" uniqKey="Vitale M" first="Maria Grazia" last="Vitale">Maria Grazia Vitale</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Million Weaver, Samuel Lewis" sort="Million Weaver, Samuel Lewis" uniqKey="Million Weaver S" first="Samuel Lewis" last="Million-Weaver">Samuel Lewis Million-Weaver</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Investigator, Madison, Wisconsin, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Independent Investigator, Madison, Wisconsin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ascierto, Paolo Antonio" sort="Ascierto, Paolo Antonio" uniqKey="Ascierto P" first="Paolo Antonio" last="Ascierto">Paolo Antonio Ascierto</name>
<affiliation wicri:level="1"><nlm:affiliation>Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy paolo.ascierto@gmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32784217</idno>
<idno type="pmid">32784217</idno>
<idno type="doi">10.1136/jitc-2020-001089</idno>
<idno type="pmc">PMC7418768</idno>
<idno type="wicri:Area/Main/Corpus">000708</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000708</idno>
<idno type="wicri:Area/Main/Curation">000708</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000708</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.</title>
<author><name sortKey="Montesarchio, Vincenzo" sort="Montesarchio, Vincenzo" uniqKey="Montesarchio V" first="Vincenzo" last="Montesarchio">Vincenzo Montesarchio</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Parrela, Roberto" sort="Parrela, Roberto" uniqKey="Parrela R" first="Roberto" last="Parrela">Roberto Parrela</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Iommelli, Chiara" sort="Iommelli, Chiara" uniqKey="Iommelli C" first="Chiara" last="Iommelli">Chiara Iommelli</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bianco, Antonella" sort="Bianco, Antonella" uniqKey="Bianco A" first="Antonella" last="Bianco">Antonella Bianco</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Manzillo, Elio" sort="Manzillo, Elio" uniqKey="Manzillo E" first="Elio" last="Manzillo">Elio Manzillo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fraganza, Fiorentino" sort="Fraganza, Fiorentino" uniqKey="Fraganza F" first="Fiorentino" last="Fraganza">Fiorentino Fraganza</name>
<affiliation wicri:level="1"><nlm:affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Palumbo, Cristiana" sort="Palumbo, Cristiana" uniqKey="Palumbo C" first="Cristiana" last="Palumbo">Cristiana Palumbo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rea, Gaetano" sort="Rea, Gaetano" uniqKey="Rea G" first="Gaetano" last="Rea">Gaetano Rea</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Murino, Patrizia" sort="Murino, Patrizia" uniqKey="Murino P" first="Patrizia" last="Murino">Patrizia Murino</name>
<affiliation wicri:level="1"><nlm:affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="De Rosa, Rosanna" sort="De Rosa, Rosanna" uniqKey="De Rosa R" first="Rosanna" last="De Rosa">Rosanna De Rosa</name>
<affiliation wicri:level="1"><nlm:affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Atripaldi, Luigi" sort="Atripaldi, Luigi" uniqKey="Atripaldi L" first="Luigi" last="Atripaldi">Luigi Atripaldi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="D Abbraccio, Maurizio" sort="D Abbraccio, Maurizio" uniqKey="D Abbraccio M" first="Maurizio" last="D'Abbraccio">Maurizio D'Abbraccio</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Curvietto, Marcello" sort="Curvietto, Marcello" uniqKey="Curvietto M" first="Marcello" last="Curvietto">Marcello Curvietto</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mallardo, Domenico" sort="Mallardo, Domenico" uniqKey="Mallardo D" first="Domenico" last="Mallardo">Domenico Mallardo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Celentano, Egidio" sort="Celentano, Egidio" uniqKey="Celentano E" first="Egidio" last="Celentano">Egidio Celentano</name>
<affiliation wicri:level="1"><nlm:affiliation>Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Grimaldi, Antonio Maria" sort="Grimaldi, Antonio Maria" uniqKey="Grimaldi A" first="Antonio Maria" last="Grimaldi">Antonio Maria Grimaldi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Palla, Marco" sort="Palla, Marco" uniqKey="Palla M" first="Marco" last="Palla">Marco Palla</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trojaniello, Claudia" sort="Trojaniello, Claudia" uniqKey="Trojaniello C" first="Claudia" last="Trojaniello">Claudia Trojaniello</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vitale, Maria Grazia" sort="Vitale, Maria Grazia" uniqKey="Vitale M" first="Maria Grazia" last="Vitale">Maria Grazia Vitale</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Million Weaver, Samuel Lewis" sort="Million Weaver, Samuel Lewis" uniqKey="Million Weaver S" first="Samuel Lewis" last="Million-Weaver">Samuel Lewis Million-Weaver</name>
<affiliation wicri:level="1"><nlm:affiliation>Independent Investigator, Madison, Wisconsin, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Independent Investigator, Madison, Wisconsin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ascierto, Paolo Antonio" sort="Ascierto, Paolo Antonio" uniqKey="Ascierto P" first="Paolo Antonio" last="Ascierto">Paolo Antonio Ascierto</name>
<affiliation wicri:level="1"><nlm:affiliation>Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy paolo.ascierto@gmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal for immunotherapy of cancer</title>
<idno type="eISSN">2051-1426</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Biomarkers, Pharmacological (blood)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (diagnostic imaging)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Interleukin-6 (blood)</term>
<term>Italy (MeSH)</term>
<term>Lymphocyte Count (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Neutrophils (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (diagnostic imaging)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Receptors, Interleukin-6 (antagonists & inhibitors)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Biomarqueurs pharmacologiques (sang)</term>
<term>Femelle (MeSH)</term>
<term>Granulocytes neutrophiles (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (imagerie diagnostique)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Interleukine-6 (sang)</term>
<term>Italie (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Numération des lymphocytes (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (imagerie diagnostique)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Récepteurs à l'interleukine-6 (antagonistes et inhibiteurs)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, Interleukin-6</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers, Pharmacological</term>
<term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Italy</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs à l'interleukine-6</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Biomarqueurs pharmacologiques</term>
<term>Infections à coronavirus</term>
<term>Interleukine-6</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphocyte Count</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neutrophils</term>
<term>Pandemics</term>
<term>Retrospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Granulocytes neutrophiles</term>
<term>Humains</term>
<term>Italie</term>
<term>Mâle</term>
<term>Numération des lymphocytes</term>
<term>Pandémies</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Italie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>STUDY DESCRIPTION</b>
</p>
<p>In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32784217</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2051-1426</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>8</Volume>
<Issue>2</Issue>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Journal for immunotherapy of cancer</Title>
<ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e001089</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2020-001089</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing.</AbstractText>
<AbstractText Label="STUDY DESCRIPTION">In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease.</AbstractText>
<AbstractText Label="CONCLUSIONS">This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.</AbstractText>
<CopyrightInformation>© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Montesarchio</LastName>
<ForeName>Vincenzo</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y" EqualContrib="Y"><LastName>Parrela</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Iommelli</LastName>
<ForeName>Chiara</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bianco</LastName>
<ForeName>Antonella</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Manzillo</LastName>
<ForeName>Elio</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fraganza</LastName>
<ForeName>Fiorentino</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Palumbo</LastName>
<ForeName>Cristiana</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rea</LastName>
<ForeName>Gaetano</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Murino</LastName>
<ForeName>Patrizia</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Rosa</LastName>
<ForeName>Rosanna</ForeName>
<Initials>R</Initials>
<Identifier Source="ORCID">0000-0001-8684-0008</Identifier>
<AffiliationInfo><Affiliation>Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Atripaldi</LastName>
<ForeName>Luigi</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>D'Abbraccio</LastName>
<ForeName>Maurizio</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Curvietto</LastName>
<ForeName>Marcello</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mallardo</LastName>
<ForeName>Domenico</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Celentano</LastName>
<ForeName>Egidio</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grimaldi</LastName>
<ForeName>Antonio Maria</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Palla</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Trojaniello</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vitale</LastName>
<ForeName>Maria Grazia</ForeName>
<Initials>MG</Initials>
<AffiliationInfo><Affiliation>Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Million-Weaver</LastName>
<ForeName>Samuel Lewis</ForeName>
<Initials>SL</Initials>
<Identifier Source="ORCID">0000-0001-9057-6326</Identifier>
<AffiliationInfo><Affiliation>Independent Investigator, Madison, Wisconsin, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ascierto</LastName>
<ForeName>Paolo Antonio</ForeName>
<Initials>PA</Initials>
<Identifier Source="ORCID">0000-0002-8322-475X</Identifier>
<AffiliationInfo><Affiliation>Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy paolo.ascierto@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Immunother Cancer</MedlineTA>
<NlmUniqueID>101620585</NlmUniqueID>
<ISSNLinking>2051-1426</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054316">Biomarkers, Pharmacological</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508603">IL6R protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>NU90V55F8I</RegistryNumber>
<NameOfSubstance UI="C000592401">sarilumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Immunother Cancer. 2020 Sep;8(2):</RefSource>
<PMID Version="1">32895295</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054316" MajorTopicYN="N">Biomarkers, Pharmacological</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">case reports</Keyword>
<Keyword MajorTopicYN="Y">immunomodulation</Keyword>
<Keyword MajorTopicYN="Y">inflammation mediators</Keyword>
</KeywordList>
<CoiStatement>Competing interests: AMG: advisory and consultant role for BMS, MSD and Novartis; and travel grants from BMS, Merck Serono, Pierre Fabre, Roche and Novartis. PAA: consultant/advisory role for Bristol-Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, MedImmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, and Nektar; research funds from Bristol-Myers Squibb, Roche-Genentech, and Array; and travel support from MSD.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32784217</ArticleId>
<ArticleId IdType="pii">jitc-2020-001089</ArticleId>
<ArticleId IdType="doi">10.1136/jitc-2020-001089</ArticleId>
<ArticleId IdType="pmc">PMC7418768</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):e6-e12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283162</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25190079</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Discov. 2016 Jun;6(6):664-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27076371</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Immunopharmacol. 2020 Jul;84:106504</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32304994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2020 Aug;146(2):325-327</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32479759</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncology. 2020;98(3):131-137</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31958792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>QJM. 2020 Jul 1;113(7):474-481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32181807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Rev Allergy Immunol. 2016 Apr;50(2):140-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26797962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunother Cancer. 2020 May;8(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32385146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):769-777</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32176772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine. 2018 Apr;104:8-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29414327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Jun;18(6):1324-1329</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32306492</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 6;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32250385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Clin Immunol. 2019 Aug;15(8):813-822</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31219357</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Hematol. 2020 Jul;95(7):834-847</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32282949</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):e41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32212516</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2020 Jul;146(1):1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32344056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101623</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32179124</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am Soc Clin Oncol Educ Book. 2019 Jan;39:433-444</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31099694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):425-434</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2020 Aug;2(8):e474-e484</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32835257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Obesity (Silver Spring). 2020 Jul;28(7):1200-1204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32352637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer. 2016 Sep 15;122(18):2857-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27244347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32181795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 May 5;172(9):629-632</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32163542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 26;382(13):1268-1269</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hematology Am Soc Hematol Educ Program. 2015;2015:190-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26637720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171067</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 May 1;130(5):2202-2205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2020 Jul;2(7):e393-e400</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32835245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2020 Jun;215:108448</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32353634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):368-370</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2015 May;16(5):448-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25898198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22390970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2020 Aug;26(8):1941-1943</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32348233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 2016 Jul;434:1-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27049586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Obesity (Silver Spring). 2020 Jul;28(7):1195-1199</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32271993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Mar 16;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):404-412</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173241</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hematol Oncol. 2019 Jun;37 Suppl 1:48-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31187535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thorac Oncol. 2020 May;15(5):700-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32114094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine. 2005 Feb 21;29(4):169-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15652449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2001 Jan;32(1):76-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11118387</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2016 Jun 30;127(26):3321-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27207799</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2020 Jun;20(6):363-374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32346093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32242738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2020 May;214:108393</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Public Health. 2020 Apr 29;8:152</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32411652</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000708 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000708 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidSeniorV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:32784217 |texte= Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32784217" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidSeniorV1
![]() | This area was generated with Dilib version V0.6.37. | ![]() |